<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bestrabucil, a <z:chebi fb="5" ids="28830">chlorambucil</z:chebi>-<z:chebi fb="1" ids="23965">estradiol</z:chebi> conjugate known to accumulate in malignant cells irrespective of the presence or absence of <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor, was administered to a 41-year-old man with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, medium-sized cell type (LSG classification) stage IV (leukemic) </plain></SENT>
<SENT sid="1" pm="."><plain>A daily dose of 100 mg was given for two weeks and then 200 mg for a week </plain></SENT>
<SENT sid="2" pm="."><plain>The WBC dropped from 43,100/mm3 with 82% abnormal lymphocytes to 12,800/mm3, and the drug was discontinued </plain></SENT>
<SENT sid="3" pm="."><plain>It was resumed two weeks later at a daily dose of 50 mg </plain></SENT>
<SENT sid="4" pm="."><plain>Four weeks thereafter, complete remission was obtained with the disappearance of <z:hpo ids='HP_0000001'>all</z:hpo> peripheral <z:mp ids='MP_0000702'>adenopathies</z:mp> and abnormal cells from the bone marrow </plain></SENT>
<SENT sid="5" pm="."><plain>The patient remains disease-free for more than eight months on a maintenance dose of 50 mg per day </plain></SENT>
<SENT sid="6" pm="."><plain>Transient <z:hpo ids='HP_0010783'>erythema</z:hpo> and <z:hpo ids='HP_0000771'>gynecomastia</z:hpo> have been the only side effects so far observed </plain></SENT>
</text></document>